A Review of Novel Therapies for Melanoma

@article{Karimkhani2014ARO,
  title={A Review of Novel Therapies for Melanoma},
  author={C Karimkhani and R{\'e}n{\'e} Gonzalez and Robert P. Dellavalle},
  journal={American Journal of Clinical Dermatology},
  year={2014},
  volume={15},
  pages={323-337}
}
This review summarizes results from major recent trials regarding novel therapeutic agents in melanoma. The topics discussed include targeted therapy with BRAF (V-RAF murine sarcoma viral oncogene homolog B) inhibitors (vemurafenib and dabrafenib), MEK (mitogen-activated protein kinase kinase) inhibitors (trametinib), bcr-abl/c-kit/PDGF-R inhibitors (imatinib), and angiogenesis inhibitors (bevacizumab and aflibercept), as well as immunotherapy with anti-CTLA-4 (anti-cytotoxic T-lymphocyte… Expand
Immune-mediated Adverse Effects of Anti-CTLA-4 Antibody Therapy in Metastatic Melanoma
  • 2015
Pembrolizumab: A Review in Advanced Melanoma
TLDR
Pembrolizumab has an acceptable tolerability profile, with immune-related adverse events that are generally manageable/reversible, and is a valuable treatment option for patients with advanced melanoma, including those who have progressed on ipilimumab and BRAF/MEK inhibitors. Expand
New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.
TLDR
A longitudinal study tracks the course of MEKi treatment in an autochthonous imageable murine model of melanoma from initial response to therapeutic resistance, offering new insights into the basis for drug response, persistence, and resistance. Expand
Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents
TLDR
Experimental evidence is provided that LCS1269 might be considered as a new potential anticancer agent capable of overcoming multidrug resistance for DNA-damaging agents in melanoma. Expand
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
TLDR
Overall, the studies show that oncolytic virotherapy combined with immune checkpoint blockade is a promising approach to AML therapy. Expand
Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition
TLDR
KRASi functions synergistically with BRAF inhibition to reduce melanoma proliferation and to induce apoptosis independently of BRAF mutational status, and acquired resistance to BRAF inhibitors in melanoma is dependent on dynamic regulation of KRAS expression with subsequent AKT and extracellular-signal regulated kinase activation and can be overcome by KRASi. Expand
A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
TLDR
A novel perillyl alcohol-conjugated analog of TMZ, NEO212, is investigated for its ability to exert anticancer activity against MGMT-positive melanoma cells and may have potential as a more effective therapy for advanced melanoma. Expand
Abl Kinase Regulation by BRAF/ERK and Cooperation with Akt in Melanoma
TLDR
It is demonstrated that BRAFV600E/ERK play a critical role in binding, phosphorylating and regulating Abl localization and Abl/Arg activation by Src family kinases, which has functional and biological significance, driving proliferation, invasion, and switch in epithelial–mesenchymal–transition transcription factor expression. Expand
Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
TLDR
Mechanistically, combination of Celecoxib and Plumbagin decreased melanoma cell proliferation and retarded vascular development of tumors mediated by inhibition of COX-2 and STAT3 leading to decreased levels of key cyclins key on which melanomacell were dependent for survival. Expand
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells
TLDR
Effects of the small molecule MJ25, which increased the level of p53-dependent transactivation both as a single agent and in combination with nutlin-3, are described, which showed potent cytotoxicity towards melanoma cell lines, whilst having weaker effects against human normal cells. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 81 REFERENCES
Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
TLDR
It is demonstrated that the selective pan-RAF inhibitor TAK-632 suppresses RAF activity in BRAF wild-type cells with minimal RAF paradoxical activation and demonstrates potent antiproliferative effects both on NRAS-mutated melanoma cells and BRAF-mutation melanomas cells with acquired resistance to BRAF inhibitors through NRAS mutation or BRAF truncation. Expand
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
TLDR
Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced. Expand
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
TLDR
Analysis of human melanoma patient tumor biopsies before and during BRAF inhibitor treatment showed downregulation of VEGF consistent with the preclinical murine model, providing a strong rationale to evaluate the potential clinical application of combining BRAF inhibition with T-cell–based immunotherapy for the treatment of patients with melanoma. Expand
Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.
  • P. Chapman
  • Medicine
  • American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
  • 2013
TLDR
Understanding the various mechanisms of resistance will inform the attempts to prevent resistance to RAF inhibitors, and there is evidence that activation of parallel pathways, such as the PI3K/AKT pathway, may represent another mechanism of resistance. Expand
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
TLDR
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. Expand
Targeting angiogenesis in melanoma: prospects for the future
TLDR
If these trials show meaningful clinical benefit, then careful consideration will need to be given when designing second-generation trials, in the light of novel gene-directed therapies currently showing promise in melanoma. Expand
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
TLDR
Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation. Expand
The blockade of immune checkpoints in cancer immunotherapy
  • D. Pardoll
  • Biology, Medicine
  • Nature Reviews Cancer
  • 2012
TLDR
Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses. Expand
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
TLDR
Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use. Expand
Improved survival with ipilimumab in patients with metastatic melanoma.
TLDR
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Expand
...
1
2
3
4
5
...